Annals of Hepatology

Papers
(The H4-Index of Annals of Hepatology is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature183
STAT3: A key regulator in liver fibrosis95
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease79
Liver disease and outcomes among COVID-19 hospitalized patients – A systematic review and meta-analysis71
Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article67
Clinical treatment of cholangiocarcinoma: an updated comprehensive review60
Chemotherapy-associated steatohepatitis56
The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies54
The effect of liver test abnormalities on the prognosis of COVID-1949
Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)48
A systematic review and meta-analysis of the COVID-19 associated liver injury44
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C42
Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases38
Silymarin is an ally against insulin resistance: A review36
From Child-Pugh to MELD score and beyond: Taking a walk down memory lane36
The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study35
Increased serum selenium levels are associated with reduced risk of advanced liver fibrosis and all-cause mortality in NAFLD patients: National Health and Nutrition Examination Survey (NHANES) III32
Standardization of conventional chemoembolization for hepatocellular carcinoma30
The effect of Tauroursodeoxycholic acid (TUDCA) and gut microbiota on murine gallbladder stone formation29
COVID-19 and the liver: What do we know after six months of the pandemic?29
An Integrated Review of the Hepatorenal Syndrome28
Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease28
Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population27
SARS-CoV-2 another kind of liver aggressor, how does it do that?27
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis26
Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission25
0.089508056640625